(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Alx Oncology Holdings's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ALXO's revenue for 2027 to be $3,120,837,117, with the lowest ALXO revenue forecast at $3,120,837,117, and the highest ALXO revenue forecast at $3,120,837,117. On average, 1 Wall Street analysts forecast ALXO's revenue for 2028 to be $7,447,622,069, with the lowest ALXO revenue forecast at $7,447,622,069, and the highest ALXO revenue forecast at $7,447,622,069.
In 2029, ALXO is forecast to generate $6,031,607,623 in revenue, with the lowest revenue forecast at $797,559,126 and the highest revenue forecast at $11,265,656,119.